Answers are grounded in this paper and cite their sources.
The authors of the editorial ‘Cannabis potency in Europe’ (King, Carpentier & Griffiths 2005) are to be commended for their attempt to enhance the debate into cannabis disorders. This editorial furthers the view that both substances and those who use them are heterogeneous in nature. In substance misuse—and mental health research—the assumption of homogeneity has done more for efficacious research than it has for effective interventions in the clinical work place. However, I would disagree with the authors that we should not be unduly alarmed; there is some evidence to suggest that higher potency varieties of cannabis may cause more harm to human users. Advances in the area of individual differences in cannabis users have been made in recent years, spurred on partly by the intense debate over the causal links between cannabis and psychosis (e.g. Fergusson et al. 2005). However, it is not only psychosis that has been investigated; individual predictors of cannabis dependence have also been the subject of recent research (Chabrol et al. 2005). However, the nature of cannabis as a substance remains a neglected issue. My own review of the literature on withdrawal symptoms (Smith 2002) highlighted this issue and suggested that research was needed to fill the gaps in our knowledge with regard to the interaction between humans and cannabinoids in ecologically valid settings. In the editorial King and colleagues raised the question of the consequences of the use of increased strength of cannabis, making comparisons with the alcohol literature. However, cannabis is an elusive substance with properties that may preclude straightforward generalizations. Animal studies reveal a differential effect can be observed with varying doses of delta-9 tetrahydrocannabinol (THC): low doses introduced into mice produce a mix of stimulant and depressant effects while higher doses produce a more classical depressant effect leading to sedation and catalepsy in extreme cases (Dewey 1986). If higher doses are available in single hits it may be that higher concentrations of THC would be available to the more moderate user and this might affect the presentation of clinical cases. A second issue with cannabis regards the half-life of cannabinoids in the human system. Lower potency cannabis has been shown to have a half-life of around 20–30 hours in human participants (Agurell et al. 1986). If higher potency breeds have a greater ‘high’ then they may also have a shorter half-life. Higher potency or shorter-acting benzodiazepines produce more instantaneous results but have a quicker onset of withdrawal symptomatology (Rickels et al. 1986). If high-potency cannabis has a similar impact it may similarly influence the intensity of sensation when the effects wear off, affecting the frequency with which the individual consumes the drug and enhancing the risk of tolerance and dependence. A third issue is that THC, the active ingredient measured in most studies, is not the only cannabinoid found in grown samples of cannabis that has an effect on human users. Cannabidiol (CBD) has been investigated for possible use as an anticonvulsant (Consroe et al. 1991), a treatment for opiate withdrawal (Chesher 1985) and as an antipsychotic (Zuardi et al. 1995). The latter point is most relevant here, as CBD acts to block the effects of THC; this result has been found consistently in both animals and human participants (e.g. Carlini et al. 1970; Karniol et al. 1974). Karniol and colleagues showed that CBD diminished strong feelings of anxiety associated with ingestion of THC alone. Rottanburg et al. (1982) noted a greater frequency of psychoses associated with cannabis use in South Africa than in other countries. They postulated that this was due to the high THC content and absence of CBD found in plants in that region. Research to date has been unable to find a principle underlying the relative proportions of cannabinoids (Hanus 1986). However, the market-place for home-grown varieties of cannabis seed does point to a worrying trend. A company selling cannabis seeds has published the relative rates of THC and CBD in their products (The Pukka Seed Company; http://www.cannabis.ac/cat/dutch/index.html). They show the claimed THC contents of between 5.7% and 19.5% of plant weight (mean −11.6%), with CBD rates of between < 0.01% and 0.6%. CBD rates are rarely published in research reports, despite the anxiolytic and antipsychotic effects. Earlier studies into cannabis did attempt to analyse CBD rates; these found wide variations but the most potent breed found was 3% THC and 0.5% CBD (Krejci et al. 1975). This picture suggests that while THC rates are rising, CBD rates are remaining the same. If this is the case not only will high potency products be stronger they may have the potential to be more harmful. As this editorial notes, there is insufficient evidence for the formation of a conclusive picture with regard to the potential harm to users and society of high potency cannabis; but there is sufficient evidence to suggest that the area is in need of research. A more detailed classification of cannabis type or variety could greatly improve our understanding of the clinical presentation of cannabis disorders and provide legislators with a more informed literature to draw upon when considering legal changes in this area.
No takes yet. Share an insight, caveat, or question.
N. Smith (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: